882149406	882149406	CD	B-NP	O
|	|	NN	I-NP	B-protein
WHO	WHO	WP	B-NP	I-protein
|	|	VBZ	B-VP	O
39678628	39678628	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
9952304	9952304	CD	B-NP	O
|	|	CC	I-NP	O
4/18/2006	4/18/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
CORONARY	CORONARY	NNP	I-NP	I-protein
ARTERY	ARTERY	NNP	I-NP	I-protein
DISEASE	DISEASE	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Signed	Signed	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
4/18/2006	4/18/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/28/2007	10/28/2007	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
STOMBERG	STOMBERG	NN	B-NP	O
,	,	,	O	O
MARLON	MARLON	NNP	B-NP	O
MD	MD	NNP	I-NP	O
ADMISSION	ADMISSION	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
gluteal	gluteal	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
62-year-old	62-year-old	JJ	I-NP	O
man	man	NN	I-NP	O
with	with	IN	B-PP	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	IN	B-PP	O
recent	recent	JJ	B-NP	O
bare	bare	JJ	I-NP	O
metal	metal	NN	I-NP	O
stenting	stente	VBG	B-VP	O
in	in	IN	B-PP	O
August	August	NNP	B-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
CLL	CLL	NN	B-NP	O
and	and	CC	O	O
peripheral	peripheral	JJ	B-NP	O
arterial	arterial	JJ	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
admitted	admit	VBN	B-VP	O
for	for	IN	B-PP	O
increasing	increase	VBG	B-VP	O
right	right	JJ	B-NP	O
thigh	thigh	JJ	I-NP	O
pain	pain	NN	I-NP	O
and	and	CC	O	O
falling	fall	VBG	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
at	at	IN	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
complicated	complicate	VBN	I-NP	O
hospitalization	hospitalization	NN	I-NP	O
in	in	IN	B-PP	O
August	August	NNP	B-NP	O
where	where	WRB	B-ADVP	O
he	he	PRP	B-NP	O
presented	present	VBD	B-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
severe	severe	JJ	I-NP	O
right	right	JJ	I-NP	O
MRSA	MRSA	NN	I-NP	O
infection	infection	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
.	.	.	O	O

During	During	IN	B-PP	O
hospitalization	hospitalization	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
required	require	VBD	B-VP	O
a	a	DT	B-NP	O
revascularization	revascularization	NN	I-NP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-PP	O
undergoing	undergo	VBG	B-VP	O
surgery	surgery	NN	B-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
bare	bare	JJ	I-NP	O
metal	metal	NN	I-NP	O
stent	stent	NN	I-NP	O
placed	place	VBN	B-VP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
left	left	JJ	I-NP	O
anterior	anterior	JJ	I-NP	O
descending	descend	VBG	I-NP	O
artery	artery	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
his	his	PRP$	B-NP	O
stenting	stenting	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
BKA	BKA	NN	I-NP	O
to	to	TO	B-VP	O
eradicate	eradicate	VB	I-VP	O
his	his	PRP$	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
infection	infection	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
later	later	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
extremity	extremity	NN	I-NP	O
clot	clot	NN	I-NP	O
associated	associate	VBN	B-VP	O
with	with	IN	B-PP	O
central	central	JJ	B-NP	O
venous	venous	JJ	I-NP	O
catheter	catheter	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
hospital	hospital	NN	I-NP	O
in	in	IN	B-PP	O
August	August	NNP	B-NP	O
on	on	IN	B-PP	O
Lovenox	Lovenox	NNP	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
and	and	CC	O	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
plan	plan	NN	I-NP	O
that	that	IN	B-SBAR	O
his	his	PRP$	B-NP	O
Lovenox	Lovenox	NNP	I-NP	O
be	be	VB	B-VP	O
stopped	stop	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
reaching	reach	VBG	B-VP	O
a	a	DT	B-NP	O
therapeutic	therapeutic	JJ	I-NP	O
level	level	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
and	and	CC	I-NP	O
Plavix	Plavix	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
bare	bare	JJ	I-NP	O
metal	metal	NN	I-NP	O
stent	stent	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
of	of	IN	B-PP	O
24	24	CD	B-NP	O
at	at	IN	B-PP	O
rehab	rehab	NN	B-NP	O
and	and	CC	B-PP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
the	the	DT	B-NP	O
Hct	Hct	NN	I-NP	B-protein
rechecked	rechecke	VBD	B-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
18	18	CD	B-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
this	this	DT	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
transferred	transfer	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Landm	Landm	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
workup	workup	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
denies	deny	VBZ	B-VP	O
any	any	DT	B-NP	O
blood	blood	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
stool	stool	NN	I-NP	O
,	,	,	I-NP	O
melena	melena	NN	I-NP	O
,	,	,	I-NP	O
dizziness	dizziness	NN	I-NP	O
or	or	CC	I-NP	O
lightheadedness	lightheadedness	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
does	do	VBZ	B-VP	O
note	note	VB	I-VP	O
some	some	DT	B-NP	O
pain	pain	NN	I-NP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
right	right	JJ	I-NP	O
side	side	NN	I-NP	O
,	,	,	O	O
particularly	particularly	RB	B-ADVP	O
his	his	PRP$	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
thigh	thigh	NN	I-NP	O
and	and	CC	O	O
gluteal	gluteal	JJ	B-NP	O
area	area	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
denies	deny	VBZ	B-VP	O
any	any	DT	B-NP	O
recent	recent	JJ	I-NP	O
trauma	trauma	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
felt	feel	VBD	B-VP	O
some	some	DT	B-NP	O
weakness	weakness	NN	I-NP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
right	right	JJ	I-NP	O
leg	leg	NN	I-NP	O
but	but	CC	O	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
no	no	DT	B-NP	O
paresthesias	paresthesias	NN	I-NP	O
or	or	CC	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
states	state	VBZ	B-VP	O
that	that	IN	B-SBAR	O
his	his	PRP$	B-NP	O
leg	leg	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
at	at	IN	B-PP	O
all	all	DT	B-NP	O
times	time	NNS	I-NP	O
warm	warm	JJ	B-ADJP	O
.	.	.	O	O

ED	ED	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
guaiac	guaiac	JJ	B-NP	O
negative	negative	JJ	I-NP	O
and	and	CC	O	O
complained	complain	VBD	B-VP	O
of	of	IN	B-PP	O
some	some	DT	B-NP	O
mild	mild	JJ	I-NP	O
abdominal	abdominal	JJ	I-NP	O
fullness	fullness	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
received	receive	VBD	B-VP	O
an	an	DT	B-NP	O
abdominal	abdominal	JJ	I-NP	O
CT	CT	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
very	very	RB	I-NP	O
large	large	JJ	I-NP	O
right	right	JJ	I-NP	O
gluteal	gluteal	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
fresh	fresh	JJ	I-NP	O
fluid	fluid	NN	I-NP	O
levels	level	NNS	I-NP	O
suggesting	suggest	VBG	B-VP	O
acute	acute	JJ	B-NP	O
bleed	bleed	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
packed	pack	VBN	B-NP	O
red	red	JJ	I-NP	B-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
and	and	CC	O	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
potassium	potassium	NN	I-NP	O
level	level	NN	I-NP	O
of	of	IN	B-PP	O
5.8	5.8	CD	B-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
received	receive	VBD	B-VP	O
Kayexalate	Kayexalate	NNP	B-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Type	Type	NN	B-NP	O
II	II	CD	B-NP	O
diabetes	diabete	NNS	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
coronary	coronary	JJ	B-NP	O
artery	artery	NN	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
MI	MI	NN	I-NP	O
in	in	IN	B-PP	O
1997	1997	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
nonST	nonST	JJ	I-NP	O
elevation	elevation	NN	I-NP	O
MI	MI	NN	I-NP	O
in	in	IN	B-PP	O
3/29	3/29	CD	B-NP	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
catheterization	catheterization	NN	B-NP	O
.	.	.	O	O

Catheterization	Catheterization	NN	B-NP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
80	80	CD	I-NP	O
%	%	NN	I-NP	O
left	leave	VBD	B-VP	O
anterior	anterior	RB	I-VP	O
descending	descend	VBG	I-VP	O
lesion	lesion	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
stented	stente	VBN	I-VP	O
to	to	TO	B-PP	O
0	0	CD	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
bare	bare	JJ	I-NP	O
metal	metal	NN	I-NP	O
stent	stent	NN	I-NP	O
,	,	,	O	O
80	80	CD	B-NP	O
%	%	NN	I-NP	O
diagonal	diagonal	JJ	I-NP	O
and	and	CC	I-NP	O
first	first	JJ	I-NP	O
diagonal	diagonal	JJ	I-NP	O
lesion	lesion	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
100	100	CD	I-NP	O
%	%	NN	I-NP	O
circumflex	circumflex	NN	I-NP	O
lesion	lesion	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
known	know	VBN	I-VP	O
significant	significant	JJ	B-NP	O
peripheral	peripheral	JJ	I-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
left	leave	VBD	B-VP	O
TMA	TMA	NN	B-NP	O
in	in	IN	B-PP	O
4/3	4/3	CD	B-NP	O
with	with	IN	B-PP	O
fem-pop	fem-pop	NN	B-NP	O
in	in	IN	B-PP	O
4/3	4/3	CD	B-NP	O
,	,	,	O	O
left	leave	VBD	B-VP	O
foot	foot	NN	B-NP	O
debridement	debridement	NN	I-NP	O
in	in	IN	B-PP	O
5/26	5/26	CD	B-NP	O
and	and	CC	O	O
finally	finally	RB	B-ADVP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
BKA	BKA	NN	I-NP	O
in	in	IN	B-PP	O
6/26	6/26	CD	B-NP	O
He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
with	with	IN	B-PP	O
last	last	JJ	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
32	32	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
gout	gout	NN	B-NP	O
,	,	,	O	O
CLL	CLL	NN	B-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
fludarabine	fludarabine	NN	I-NP	O
x4	x4	NN	I-NP	O
cycles	cycle	NNS	I-NP	O
in	in	IN	B-PP	O
2004	2004	CD	B-NP	O
in	in	IN	B-PP	O
which	which	WDT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
stable	stable	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
residual	residual	JJ	B-NP	O
or	or	CC	I-NP	O
retroperitoneal	retroperitoneal	JJ	I-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
,	,	,	O	O
BPH	BPH	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
2.5	2.5	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
glaucoma	glaucoma	NN	B-NP	O
.	.	.	O	O

ADMISSION	ADMISSION	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Include	Include	VBP	B-VP	O
aspirin	aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
,	,	,	O	O
Niferex	Niferex	NNP	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Lovenox	Lovenox	NNP	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Plavix	Plavix	NNP	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	I-NP	O
,	,	,	O	O
diltiazem	diltiazem	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
hydralazine	hydralazine	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Lantus	Lantus	NNP	B-NP	O
42	42	CD	I-NP	O
units	unit	NNS	I-NP	O
at	at	IN	B-PP	O
night	night	NN	B-NP	O
,	,	,	O	O
NovoLog	NovoLog	NNP	B-NP	O
10	10	CD	I-NP	O
units	unit	NNS	I-NP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
,	,	,	O	O
Lopressor	Lopressor	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
Zocor	Zocor	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
night	night	NN	B-NP	O
,	,	,	O	O
Flomax	Flomax	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	I-NP	O
,	,	,	O	O
multivitamin	multivitamin	NN	B-NP	O
,	,	,	O	O
vitamin	vitamin	NN	B-NP	O
C	C	NN	I-NP	O
,	,	,	O	O
zinc	zinc	NN	B-NP	O
220	220	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Neurontin	Neurontin	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Xalatan	Xalatan	NNP	B-NP	O
one	one	CD	I-NP	O
drop	drop	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
eye	eye	NN	I-NP	O
every	every	DT	B-NP	O
evening	evening	NN	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
His	His	PRP$	B-NP	O
allergies	allergy	NNS	I-NP	O
include	include	VBP	B-VP	O
codeine	codeine	NN	B-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

Normocephalic	Normocephalic	JJ	B-NP	O
,	,	,	I-NP	O
atraumatic	atraumatic	JJ	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
eyes	eye	NNS	I-NP	O
were	be	VBD	B-VP	O
anicteric	anicteric	JJ	B-ADJP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
extraocular	extraocular	JJ	I-NP	O
membranes	membrane	NNS	I-NP	O
were	be	VBD	B-VP	O
intact	intact	JJ	B-ADJP	O
.	.	.	O	O

Mucous	Mucous	JJ	B-NP	O
membranes	membrane	NNS	I-NP	O
were	be	VBD	B-VP	O
moist	moist	NN	B-NP	O
without	without	IN	B-PP	O
exudates	exudate	NNS	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
neck	neck	NN	I-NP	O
was	be	VBD	B-VP	O
supple	supple	NN	B-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
full	full	JJ	B-NP	O
range	range	NN	I-NP	O
of	of	IN	B-PP	O
motion	motion	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	B-protein
had	have	VBD	B-VP	I-protein
2	2	CD	B-NP	I-protein
+	+	SYM	I-NP	O
carotid	carotid	NN	I-NP	O
pulses	pulse	NNS	I-NP	O
on	on	IN	B-PP	O
both	both	DT	B-NP	O
sides	side	NNS	I-NP	O
without	without	IN	B-PP	O
any	any	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
bruits	bruit	NNS	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
jugular	jugular	JJ	I-NP	O
venous	venous	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
approximately	approximately	RB	B-NP	O
8	8	CD	I-NP	O
cm	cm	NN	I-NP	O
of	of	IN	B-PP	O
water	water	NN	B-NP	O
at	at	IN	B-PP	O
30	30	CD	B-NP	O
degrees	degree	NNS	I-NP	O
of	of	IN	B-PP	O
elevation	elevation	NN	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
lungs	lung	NNS	I-NP	O
were	be	VBD	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
bibasilar	bibasilar	JJ	B-NP	O
crackles	crackle	NNS	I-NP	O
with	with	IN	B-PP	O
left	left	JJ	B-NP	O
side	side	NN	I-NP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
right	right	JJ	B-ADJP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O
exam	exam	NN	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
regular	regular	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	O	O
S2	S2	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
I/VI	I/VI	NN	I-NP	B-protein
systolic	systolic	JJ	I-NP	I-protein
ejection	ejection	NN	I-NP	I-protein
murmur	murmur	NN	I-NP	I-protein
at	at	IN	B-PP	I-protein
his	his	PRP$	B-NP	I-protein
base	base	NN	I-NP	I-protein
.	.	.	O	O

This	This	DT	B-NP	O
seemed	seem	VBD	B-VP	O
to	to	TO	I-VP	O
radiate	radiate	VB	I-VP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
axilla	axilla	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
nondistended	nondistended	JJ	B-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
normal	normal	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
in	in	IN	B-PP	O
all	all	DT	B-NP	O
four	four	CD	I-NP	O
quadrants	quadrant	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
hepatosplenomegaly	hepatosplenomegaly	NN	I-NP	O
or	or	CC	I-NP	O
masses	mass	NNS	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
extremities	extremity	NNS	I-NP	O
are	be	VBP	B-VP	O
notable	notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
right-sided	right-sided	JJ	I-NP	O
gluteal	gluteal	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
with	with	IN	B-PP	O
fullness	fullness	NN	B-NP	O
and	and	CC	I-NP	O
thickening	thickening	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
does	do	VBZ	B-VP	O
have	have	VB	I-VP	O
1	1	CD	B-NP	O
+	+	SYM	I-NP	O
palpable	palpable	JJ	I-NP	O
DP	DP	NN	I-NP	O
pulse	pulse	NN	I-NP	O
on	on	IN	B-PP	O
that	that	DT	B-NP	O
side	side	NN	I-NP	O
confirmed	confirm	VBD	B-VP	O
with	with	IN	B-PP	O
Doppler	Doppler	NNP	B-NP	O
.	.	.	O	O

Skin	Skin	NN	B-NP	O
was	be	VBD	B-VP	O
without	without	IN	B-PP	O
rash	rash	NN	B-NP	O
,	,	,	O	O
ecchymosis	ecchymosis	NN	B-NP	O
,	,	,	O	O
or	or	CC	O	O
petechiae	petechiae	FW	B-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
neurological	neurological	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
intact	intact	JJ	B-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
alert	alert	JJ	B-NP	O
and	and	CC	I-NP	O
oriented	orient	VBN	I-NP	O
x3	x3	NN	I-NP	O
.	.	.	O	O

Cranial	Cranial	NNP	B-NP	O
nerves	nerve	VBZ	B-VP	O
II	II	CD	B-NP	O
through	through	IN	B-PP	O
XII	XII	NN	B-NP	B-DNA
were	be	VBD	B-VP	O
grossly	grossly	RB	B-ADJP	O
intact	intact	JJ	I-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
intact	intact	JJ	B-NP	O
motor	motor	NN	I-NP	O
and	and	CC	I-NP	O
sensation	sensation	NN	I-NP	O
in	in	IN	B-PP	O
his	his	PRP$	B-NP	O
right	right	JJ	I-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
along	along	IN	B-PP	O
with	with	IN	B-PP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
neuropathy	neuropathy	NN	I-NP	O
with	with	IN	B-PP	O
sensory	sensory	JJ	B-NP	O
loss	loss	NN	I-NP	O
up	up	IN	B-PP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

Admission	Admission	NN	B-NP	O
EKG	EKG	NN	I-NP	O
is	be	VBZ	B-VP	O
normal	normal	JJ	B-ADJP	O
for	for	IN	B-PP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
,	,	,	O	O
normal	normal	JJ	B-NP	O
axis	axis	NN	I-NP	O
,	,	,	O	O
old	old	JJ	B-NP	O
T-wave	T-wave	NN	I-NP	O
inversions	inversion	NNS	I-NP	O
in	in	IN	B-PP	O
I	I	NN	B-NP	O
and	and	CC	I-NP	O
aVL	aVL	NN	I-NP	O
and	and	CC	O	O
an	an	DT	B-NP	O
isolated	isolate	VBN	I-NP	O
ST	ST	NN	I-NP	O
elevation	elevation	NN	I-NP	O
in	in	IN	B-PP	O
lead	lead	NN	B-NP	B-protein
2	2	CD	I-NP	I-protein
.	.	.	O	O

Notable	Notable	JJ	B-NP	O
studies	study	NNS	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
included	include	VBD	B-VP	O
CT	CT	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
abdomen	abdomen	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
new	new	JJ	I-NP	O
right	right	JJ	I-NP	O
gluteal	gluteal	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
with	with	IN	B-PP	O
fluid	fluid	NN	B-NP	O
levels	level	NNS	I-NP	O
suggesting	suggest	VBG	B-VP	O
acute	acute	JJ	B-NP	O
bleed	bleed	NN	I-NP	O
.	.	.	O	O

ADMISSION	ADMISSION	NN	B-NP	O
LABS	LABS	NN	I-NP	O
:	:	:	O	O
Potassium	Potassium	NN	B-NP	O
5.8	5.8	CD	I-NP	O
,	,	,	O	O
creatinine	creatinine	NN	B-NP	B-protein
2.1	2.1	CD	I-NP	I-protein
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	O
of	of	IN	B-PP	O
22.3	22.3	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
MRI	MRI	NN	I-NP	B-protein
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
brain	brain	NN	I-NP	O
done	do	VBN	B-VP	O
on	on	IN	B-PP	O
5/29/06	5/29/06	CD	B-NP	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
subacute	subacute	JJ	B-NP	O
infarction	infarction	NN	I-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
anterior	anterior	JJ	I-NP	O
internal	internal	JJ	I-NP	O
capsule	capsule	NN	I-NP	O
and	and	CC	O	O
chronic	chronic	JJ	B-NP	O
occlusion	occlusion	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
internal	internal	JJ	I-NP	O
carotid	carotid	NN	I-NP	O
and	and	CC	O	O
old	old	JJ	B-NP	O
left	left	JJ	I-NP	O
parietal	parietal	JJ	I-NP	O
stroke	stroke	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
done	do	VBN	B-VP	O
on	on	IN	B-PP	O
10/1/06	10/1/06	CD	B-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
30-35	30-35	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
trace	trace	VBP	B-VP	O
aortic	aortic	JJ	B-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
trace	trace	VBP	B-VP	O
mitral	mitral	JJ	B-NP	O
regurgitation	regurgitation	NN	I-NP	O
,	,	,	O	O
trace	trace	VBP	B-VP	O
tricuspid	tricuspid	JJ	B-NP	O
regurgitation	regurgitation	NN	I-NP	O
and	and	CC	I-NP	O
PA	PA	NN	I-NP	O
systolic	systolic	JJ	I-NP	O
pressures	pressure	NNS	I-NP	O
of	of	IN	B-PP	O
33	33	CD	B-NP	O
+	+	SYM	I-NP	O
right	right	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
pressure	pressure	NN	I-NP	O
.	.	.	O	O

IMPRESSION	IMPRESSION	NN	B-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
62-year-old	62-year-old	JJ	I-NP	O
man	man	NN	I-NP	O
admitted	admit	VBN	B-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
falling	fall	VBG	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
evolving	evolve	VBG	I-NP	O
right	right	JJ	I-NP	O
gluteal	gluteal	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
supratherapeutic	supratherapeutic	JJ	B-NP	O
anticoagulation	anticoagulation	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
PROBLEM	PROBLEM	NN	I-NP	O
IS	IS	VBZ	B-VP	O
AS	AS	JJ	B-NP	O
FOLLOWS	FOLLOWS	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Right	Right	RB	B-NP	O
gluteal	gluteal	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
low	low	JJ	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
being	be	VBG	B-VP	O
on	on	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
anticoagulant	anticoagulant	JJ	I-NP	O
and	and	CC	I-NP	O
antiplatelet	antiplatelet	JJ	I-NP	O
drugs	drug	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
right	right	JJ	B-NP	O
gluteal	gluteal	JJ	I-NP	O
hematoma	hematoma	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
responsible	responsible	JJ	B-ADJP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
drop	drop	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
,	,	,	O	O
Lovenox	Lovenox	NN	B-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Plavix	Plavix	NN	B-NP	O
were	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
held	hold	VBN	I-VP	O
.	.	.	O	O

He	He	PRP	B-NP	O
received	receive	VBD	B-VP	O
vitamin	vitamin	NN	B-NP	O
K	K	NN	I-NP	O
and	and	CC	O	O
three	three	CD	B-NP	O
units	unit	NNS	I-NP	O
of	of	IN	B-PP	O
FFP	FFP	NN	B-NP	B-protein
to	to	TO	B-VP	O
reverse	reverse	VB	I-VP	O
his	his	PRP$	B-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
transfused	transfuse	VBN	I-VP	O
a	a	DT	B-NP	O
total	total	NN	I-NP	O
of	of	IN	B-PP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
of	of	IN	B-PP	O
PRBCs	PRBC	NNS	B-NP	B-cell_type
for	for	IN	B-PP	O
a	a	DT	B-NP	O
goal	goal	NN	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
of	of	IN	B-PP	O
30	30	CD	B-NP	O
given	give	VBN	B-VP	O
his	his	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
and	and	CC	I-NP	O
neurologic	neurologic	JJ	I-NP	O
disease	disease	NN	I-NP	O
as	as	IN	B-SBAR	O
described	describe	VBN	B-VP	O
below	below	IN	B-PP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
further	further	JJ	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
drop	drop	NN	I-NP	O
.	.	.	O	O

Given	Give	VBN	B-VP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
anticoagulated	anticoagulate	VBN	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
right	right	JJ	B-NP	O
upper	upper	JJ	I-NP	O
extremity	extremity	NN	I-NP	O
DVT	DVT	NN	I-NP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
indication	indication	NN	I-NP	O
for	for	IN	B-PP	O
anticoagulation	anticoagulation	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
and	and	CC	I-NP	O
catheter	catheter	NN	I-NP	B-protein
associated	associate	VBN	I-NP	I-protein
clot	clot	NN	I-NP	I-protein
is	be	VBZ	B-VP	O
somewhat	somewhat	RB	B-ADJP	O
murky	murky	JJ	I-ADJP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
would	would	MD	B-VP	O
not	not	RB	I-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
addition	addition	NN	B-NP	O
of	of	IN	B-PP	O
anticoagulation	anticoagulation	NN	B-NP	O
and	and	CC	O	O
therefore	therefore	RB	B-ADVP	O
his	his	PRP$	B-NP	O
Lovenox	Lovenox	NN	I-NP	O
and	and	CC	I-NP	O
Coumadin	Coumadin	NN	I-NP	O
were	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
aspirin	aspirin	NN	I-NP	O
and	and	CC	O	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
Plavix	Plavix	NN	I-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
Hct	Hct	NN	I-NP	B-protein
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Non-ST-elevation	Non-ST-elevation	JJ	B-NP	O
MI	MI	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
in	in	IN	B-PP	O
August	August	NNP	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
known	know	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
three-vessel	three-vessel	JJ	B-NP	O
coronary	coronary	JJ	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
underwent	underwent	JJ	B-NP	O
stenting	stenting	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
LAD	LAD	NN	I-NP	B-protein
with	with	IN	B-PP	O
a	a	DT	B-NP	O
bare	bare	JJ	I-NP	O
metal	metal	NN	I-NP	O
stent	stent	NN	I-NP	O
on	on	IN	B-PP	O
6/28/06	6/28/06	CD	B-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
discussion	discussion	NN	B-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
cardiologist	cardiologist	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
and	and	CC	I-NP	O
Plavix	Plavix	NN	I-NP	O
given	give	VBN	B-PP	O
the	the	DT	B-NP	O
evolution	evolution	NN	I-NP	O
of	of	IN	B-PP	O
hematoma	hematoma	NN	B-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
acute	acute	JJ	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
drop	drop	NN	I-NP	O
.	.	.	O	O

During	During	IN	B-PP	O
his	his	PRP$	B-NP	B-DNA
lowest	low	JJS	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
period	period	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
lateral	lateral	JJ	B-NP	O
ST	ST	NN	I-NP	O
depressions	depression	NNS	I-NP	O
and	and	CC	O	O
this	this	DT	B-NP	O
corresponded	correspond	VBD	B-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
troponin	troponin	NN	I-NP	O
leak	leak	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
peak	peak	JJ	I-NP	O
troponin	troponin	NN	I-NP	O
of	of	IN	B-PP	O
2.46	2.46	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
etiology	etiology	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
demand	demand	NN	B-NP	O
related	relate	VBN	B-VP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
profound	profound	JJ	I-NP	O
anemia	anemia	NN	I-NP	O
and	and	CC	B-PP	O
on	on	IN	B-PP	O
correction	correction	NN	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
anemia	anemia	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
ST	ST	NN	I-NP	O
depressions	depression	NNS	I-NP	O
resolved	resolve	VBN	B-VP	O
fully	fully	RB	B-ADVP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
troponins	troponin	NNS	I-NP	O
trended	trend	VBN	B-VP	O
downward	downward	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
known	know	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
presumed	presume	VBN	I-NP	O
ischemic	ischemic	JJ	I-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
following	follow	VBG	B-PP	O
his	his	PRP$	B-NP	O
nonST	nonST	JJ	I-NP	O
elevation	elevation	NN	I-NP	O
MI	MI	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
30-35	30-35	CD	B-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
repeat	repeat	NN	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
done	do	VBN	B-VP	O
in	in	IN	B-PP	O
one	one	CD	B-NP	O
month	month	NN	I-NP	O
's	's	POS	B-NP	O
time	time	NN	I-NP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
whether	whether	IN	B-SBAR	O
or	or	CC	O	O
not	not	RB	O	O
he	he	PRP	B-NP	O
would	would	MD	B-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
an	an	DT	B-NP	O
implantable	implantable	JJ	I-NP	O
cardiac	cardiac	JJ	I-NP	O
defibrillator	defibrillator	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
medications	medication	NNS	I-NP	O
were	be	VBD	B-VP	O
adjusted	adjust	VBN	I-VP	O
as	as	IN	B-PP	O
follows	follow	VBZ	B-VP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
medications	medication	NNS	I-NP	O
were	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
held	hold	VBN	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
stroke-like	stroke-like	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
when	when	WRB	B-ADVP	O
his	his	PRP$	B-NP	O
low	low	JJ	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
detailed	detail	VBN	B-VP	O
below	below	IN	B-PP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
they	they	PRP	B-NP	O
were	be	VBD	B-VP	O
slowly	slowly	RB	I-VP	O
added	add	VBN	I-VP	O
back	back	RB	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
tolerated	tolerate	VBD	B-VP	O
slow	slow	JJ	B-NP	O
titration	titration	NN	I-NP	O
of	of	IN	B-PP	O
beta-blocker	beta-blocker	NN	B-NP	O
to	to	TO	B-PP	O
goal	goal	NN	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
and	and	CC	O	O
also	also	RB	B-ADVP	O
addition	addition	NN	B-NP	O
of	of	IN	B-PP	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
important	important	JJ	B-ADJP	O
given	give	VBN	B-PP	O
his	his	PRP$	B-NP	O
extensive	extensive	JJ	I-NP	O
peripheral	peripheral	JJ	I-NP	O
vascular	vascular	JJ	I-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
low	low	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Recrudescence	Recrudescence	NN	B-NP	O
of	of	IN	B-PP	O
stroke-like	stroke-like	JJ	B-NP	O
symptoms	symptom	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
setting	setting	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
acute	acute	JJ	I-NP	O
hematocrit	hematocrit	NN	I-NP	O
drop	drop	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
worsening	worsen	VBG	I-VP	O
slurred	slur	VBN	B-NP	O
speech	speech	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
facial	facial	JJ	I-NP	O
droop	droop	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
does	do	VBZ	B-VP	O
carry	carry	VB	I-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
left	left	JJ	B-NP	O
internal	internal	JJ	I-NP	O
carotid	carotid	NN	I-NP	O
occlusion	occlusion	NN	I-NP	O
and	and	CC	O	O
left-sided	left-sided	JJ	B-NP	O
stroke	stroke	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
Neurology	Neurology	NNP	I-NP	O
team	team	NN	I-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
for	for	IN	B-PP	O
these	these	DT	B-NP	O
acute	acute	JJ	I-NP	O
deficits	deficit	NNS	I-NP	O
and	and	CC	O	O
requested	request	VBD	B-VP	O
an	an	DT	B-NP	O
MRI	MRI	NN	I-NP	B-protein
.	.	.	O	O

The	The	DT	B-NP	O
MRI	MRI	NN	I-NP	B-protein
showed	show	VBD	B-VP	O
basically	basically	RB	B-NP	O
old	old	JJ	I-NP	O
known	known	JJ	I-NP	O
strokes	stroke	NNS	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
subacute	subacute	JJ	I-NP	O
right	right	JJ	I-NP	O
internal	internal	JJ	I-NP	O
capsule	capsule	NN	I-NP	O
stroke	stroke	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
unrelated	unrelated	JJ	B-ADJP	O
to	to	TO	B-PP	O
his	his	PRP$	B-NP	O
current	current	JJ	I-NP	O
symptomatology	symptomatology	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
initially	initially	RB	B-ADVP	O
had	have	VBD	B-VP	O
his	his	PRP$	B-NP	O
antihypertensives	antihypertensive	NNS	I-NP	O
to	to	TO	B-VP	O
allow	allow	VB	I-VP	O
for	for	IN	B-PP	O
maximal	maximal	JJ	B-NP	O
perfusion	perfusion	NN	I-NP	O
pressure	pressure	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
as	as	IN	B-PP	O
his	his	PRP$	B-NP	O
coagulopathy	coagulopathy	NN	I-NP	O
resolved	resolve	VBN	B-VP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
stress	stress	NN	I-NP	O
that	that	WDT	B-NP	O
resulted	result	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
recrudescence	recrudescence	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
old	old	JJ	I-NP	O
stroke-like	stroke-like	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
was	be	VBD	B-VP	O
resolved	resolve	VBN	I-VP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
able	able	JJ	B-NP	O
tolerate	tolerate	JJ	I-NP	O
,	,	,	I-NP	O
further	further	JJ	I-NP	O
addition	addition	NN	I-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
antihypertensives	antihypertensive	NNS	I-NP	O
without	without	IN	B-PP	O
further	further	JJ	B-NP	O
incident	incident	NN	I-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
and	and	CC	O	O
given	give	VBN	B-VP	O
his	his	PRP$	B-NP	O
recent	recent	JJ	I-NP	O
below	below	IN	B-PP	O
the	the	DT	B-NP	O
knee	knee	NN	I-NP	O
amputation	amputation	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
best	well	RBS	B-VP	O
served	serve	VBN	I-VP	O
by	by	IN	B-PP	O
going	go	VBG	B-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-VP	O
rehab	rehab	VB	I-VP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
His	His	PRP$	B-NP	O
discharged	discharged	JJ	I-NP	O
medications	medication	NNS	I-NP	O
are	be	VBP	B-VP	O
as	as	IN	B-SBAR	O
follows	follow	VBZ	B-VP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Tylenol	Tylenol	NN	B-NP	O
650	650	CD	I-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Aspirin	Aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Lovenox	Lovenox	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Nexium	Nexium	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
and	and	CC	I-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
night	night	NN	B-NP	O
which	which	WDT	B-NP	O
his	his	PRP$	B-NP	O
IO	IO	NN	I-NP	O
goals	goal	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
about	about	IN	B-NP	O
-500	-500	CD	I-NP	O
cc	cc	NN	I-NP	O
of	of	IN	B-PP	O
fluid	fluid	NN	B-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Neurontin	Neurontin	NN	B-NP	B-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

Aspart	Aspart	RB	B-NP	O
10	10	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneous	subcutaneous	JJ	B-ADJP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Aspart	Aspart	RB	B-ADVP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Glargine	Glargine	NN	B-NP	B-protein
42	42	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
daily	daily	RB	B-ADVP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Xalatan	Xalatan	NN	B-NP	O
one	one	CD	I-NP	O
drop	drop	NN	I-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Lisinopril	Lisinopril	NNP	B-NP	O
15	15	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

12	12	CD	B-NP	O
.	.	.	O	O

Toprol-XL	Toprol-XL	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

13	13	CD	B-NP	O
.	.	.	O	O

Niferex	Niferex	NNP	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Zocor	Zocor	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
at	at	IN	B-PP	O
night	night	NN	B-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Flomax	Flomax	NN	B-NP	O
0.4	0.4	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
one	one	CD	I-NP	O
tablet	tablet	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Zinc	Zinc	NN	B-NP	O
220	220	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Plavix	Plavix	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
po	po	NN	I-NP	O
daily	daily	JJ	I-NP	O
FOLLOW-UP	FOLLOW-UP	NN	I-NP	O
PLAN	PLAN	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
to	to	TO	B-VP	O
call	call	VB	I-VP	O
his	his	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Lupe	Lupe	NNP	I-NP	O
Bario	Bario	NNP	I-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
cardiologist	cardiologist	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Mraw	Mraw	NNP	I-NP	O
,	,	,	O	O
following	follow	VBG	B-PP	O
discharge	discharge	NN	B-NP	O
from	from	IN	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
repeat	repeat	NN	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
his	his	PRP$	B-NP	O
candidacy	candidacy	NN	I-NP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
implantable	implantable	JJ	I-NP	O
cardiac	cardiac	JJ	I-NP	O
defibrillator	defibrillator	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
6-5034970	6-5034970	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
DALENBERG	DALENBERG	NNP	B-NP	O
,	,	,	O	O
ALEX	ALEX	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
REICHMANN	REICHMANN	NNP	B-NP	O
,	,	,	O	O
TERRELL	TERRELL	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
1908962	1908962	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
4/30/06	4/30/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
4/30/06	4/30/06	CD	B-NP	O

